1. Prevention of meningococcal infection in the United States: current recommendations and future considerations;Baker;J Adolesc Health,2016
2. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study;Chen;Lancet Infect Dis,2018
3. Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents – results from a randomized, controlled, observer-blind phase ii study;Welsch;Vaccine,2018
4. ClinicalTrials.gov. A trial to describe the immunogenicity and safety of 2 doses of bivalent rLP2086 (Trumenba) and a pentavalent meningococcal vaccine in healthy subjects ≥10 to <26 years of age. Available from: https://clinicaltrials.gov/ct2/show/NCT03135834?cond=meningococcal+vaccines&rank=1 [accessed 24.02.19].
5. Red Nacional de Vigilancia Epidemiológica. Enfermedad meningocócica. Vigilancia de la temporada 2017-2018. Available from: http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/fd-enfermedades-prevenibles-vacunacion/pdf_2019/RENAVE_EMI-2017-18.pdf [accessed 16.02.19].